Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | XB010 |
| Synonyms | |
| Therapy Description |
XB010 is an antibody-drug conjugate (ADC) comprising a monoclonal antibody targeting 5T4 (TPBG) linked to monomethyl auristatin E (MMAE), which potentially induces cell cycle arrest and apoptosis in tumor cells expressing 5T4 (TPBG) (NCI Drug Dictionary). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| XB010 | XB-010|XB 010 | XB010 is an antibody-drug conjugate (ADC) comprising a monoclonal antibody targeting 5T4 (TPBG) linked to monomethyl auristatin E (MMAE), which potentially induces cell cycle arrest and apoptosis in tumor cells expressing 5T4 (TPBG) (NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06545331 | Phase I | Pembrolizumab + XB010 XB010 | Study of XB010 in Subjects With Solid Tumors | Recruiting | USA | 0 |